Clinical Characteristics and Outcomes of Polyarteritis Nodosa – an International Study
Omer Karadag,Ertugrul Cagri Bolek,Gizem Ayan,Aladdin J Mohammad,Peter C. Grayson,Christian Pagnoux,Eduardo Martín‐Nares,Sara Monti,Yoshiyuki Abe,Federico Alberici,Fatma Alibaz‐Oner,David Cuthbertson,Lorenzo Dagna,Haner Direskeneli,Nader A. Khalidi,Curry Koening,Carol A. Langford,Carol A. McAlear,Paul A. Monach,Luca Moroni,Roberto Padoan,Phillip Seo,Kenneth Warrington,Alojzija Hocevar,Andrea Hinojosa‐Azaola,Shunsuke Furuta,Giacomo Emmi,Seza Ozen,David Jayne,Peter A. Merkel,GLOBAL‐PAN
DOI: https://doi.org/10.1002/art.42817
2024-02-13
Arthritis & Rheumatology
Abstract:Objective To describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL‐PAN). Methods Patients with PAN recruited between 1990 and 2020 from observational cohorts of 9 countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency (EMA) classification algorithm. Patients with PAN related to hepatitis B virus (HBV) (n=12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n=16) or familial Mediterranean fever (n=11), were excluded. Data regarding organ involvement, relapse, disease‐related damage, and survival were analyzed. Results 358 patients (female/male: 174/184), including systemic PAN (sPAN, n=282) and cutaneous PAN (cPAN, n=76), were included. Twenty‐five were pediatric‐onset. Mean (SD) age at diagnosis was 44.3 (18.1) years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement, and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (inter‐quartile range) 59.6 (99.5) months of follow‐up, relapse occurred in 48.5% of patients. One, 5‐ and 10‐year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of mortality for sPAN included age ≥ 65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement . Conclusion The spectrum of PAN remains a complex, multi‐faceted disease. Relapse is common. Age ≥ 65 years and serum creatinine >140 μmol/L at diagnosis, gastrointestinal and CNS involvement are independent predictors of mortality in sPAN.
rheumatology